Think Beyond The Therapy: Demystifying The Complexities Of Cell And Gene Therapy Commercialization

By Dale Lippert Sr., RN, BS, MS, Senior Director, Client Success Leader, and Lee Ann Steadman, Senior Vice President, EVERSANA

While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to the therapy and supporting patients through the treatment journey. This is true for almost every specialty product, but it is especially important for cell and gene therapies, given the high cost and complexity of administering these innovative new therapies.

Behind the scenes of the cell and gene therapy product flow, many time-critical events need precise coordination. A customer-centric support model is needed to ensure a simplified, enhanced experience for all treatment stakeholders. This article walks through the considerations when building that model for cell and gene therapies.